LCM Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$634K Buy
1,212
+16
+1% +$8.19K 0.27% 50
2026
Q2
$594K Buy
1,196
+38
+3% +$16.8K 0.26% 51
2026
Q1
$517K Buy
1,158
+23
+2% +$10.7K 0.26% 50
2025
Q4
$515K Sell
1,135
-10
-0.9% -$4.31K 0.25% 47
2025
Q3
$448K Sell
1,145
-3
-0.3% -$1.25K 0.22% 53
2025
Q2
$511K Buy
1,148
+4
+0.3% +$1.84K 0.27% 50
2025
Q1
$555K Buy
1,144
+71
+7% +$33.1K 0.33% 47
2024
Q4
$432K Buy
1,073
+19
+2% +$8.81K 0.24% 55
2024
Q3
$490K Buy
1,054
+58
+6% +$27.9K 0.28% 51
2024
Q2
$467K Buy
996
+56
+6% +$24.3K 0.29% 49
2024
Q1
$393K Buy
940
+14
+2% +$5.92K 0.25% 55
2023
Q4
$377K Buy
926
+16
+2% +$5.91K 0.27% 55
2023
Q3
$316K Buy
910
+113
+14% +$39.5K 0.26% 57
2023
Q2
$280K Buy
797
+39
+5% +$13.1K 0.23% 67
2023
Q1
$239K Buy
+758
New +$227K 0.21% 74

Other funds holding VRTX

LCM Capital Management's VRTX Position: Q3 2026 in Review

LCM Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q3 2026, buying an estimated $8.19K and bringing the position to 1,212 shares worth $634K. The position accounts for 0.27% of the portfolio, ranked #50.

LCM Capital Management first reported a position in VRTX in Q1 2023 and has held it in 15 quarters since. 1,793 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • LCM Capital Management held 1,212 shares of Vertex Pharmaceuticals worth $634K as of Q3 2026.
  • LCM Capital Management bought 16 Vertex Pharmaceuticals shares in Q3 2026, an estimated $8.19K.
  • Vertex Pharmaceuticals made up 0.27% of LCM Capital Management's portfolio in Q3 2026, its #50 holding.
  • LCM Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 15 quarters since.
  • 1,793 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on LCM Capital Management's 13F filing for Q3 2026, filed 20 Oct 2026.